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 The aim of the contemporary research work was to develop the controlled release tablets of 
esomeprazole. Esomeprazole having a shorter biological half life (1-1.5 hours) hence we are 
selected as a controlled release tablet, So it should be minimize the dose dumping problems 
and avoid fluctuations in plasma drug concentrations. To maintain constant therapeutic levels 
of the drug over 24 hours. Compatibility studies was execution during FTIR and DSC shown 
that there was absence of probable chemical interaction between pure drug and excipients.  
Controlled release tablets were prepared by direct compression method using altered 
concentrations of Eudragit-S 100, Eudragit-L 100 and Eudragit-RSPO. Esomeprazole dose 
was fixed as 20 mg. Total weight of the tablet was considered as 100 mg. Polymers were used 
in the concentration of 20 and 40 mg. Prepared compositions were evaluating the various 
physicochemical parameters such as weight variation, hardness, friability, thickness and drug 
content. All the compositions were resulted in adequate Pharmacopoeial limits. Whereas from 
the dissolution studies it was evident that the formulation (F-6) showed better desired drug 
release pattern i.e., 97.47% in 24 hours. It followed Zero Order release kinetics mechanism. 
As the consequence of this amendment it could conclude that the compositions rally the 
needed theoretical drug release profile as well as has the controlled action i.e., retarded the 
drug release, Hence so the release is for a long time and thus more Bioavailability. The 
optimised formula shall be utilized for the formulation development and other studies like 
bioequivalence study, for triumphant initiation of the product. 
Please cite this article in press as Y. Naveen Kumar et al. Formulation Development and Invitro Evaluation of Esomeprazole 
Controlled Release Tablets by Using Various Grades of Eudragit Polymers. Indo American Journal of Pharmaceutical 
Research.2017:7(01). 
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INTRODUCTION 
Esomeprazole is a proton pump inhibitor (PPI) which blocks the production of acid by the stomach. It is used in the treatment 
of Peptic ulcer disease, Gastroesophageal reflux disease (GERD) and Zollinger-Ellison Syndrome. 
The goal in designing a controlled delivery system is to reduce the frequency of dosing or to increase the effectiveness of the 
drug by localization at the site of action, reducing the dose required or providing uniform drug delivery.  
The primary objectives of controlled drug delivery are to ensure safety and to improve efficacy of drugs as well as patient 
compliance. This is achieved by better control of plasma drug levels and less frequent dosing. 
[1, 2]
 
To formulate and evaluate Esomeprazole controlled release tablets using different polymers such as Eudragit grades, Talc, 
Magnesium Stearate and Di Calcium Phosphate. 
The Main Objective of this study was to improve the bioavailability, reduce the number of doses and to increase patient 
compliance it was formulated as controlled release tablets. 
 
MATERIALS AND METHODS 
Esomeprazole was a procured from Micro Labs, Bangalore, Eudragit grades was supplied by Yarrow Chem. Products, 
Mumbai, and Talc, Magnesium Stearate, Di calcium phosphate were supplied by Signet Chemical Corporation, Mumbai, India. 
 
METHODOLOGY 
Analytical method development: 
Determination of absorption maxima: 
A solution of containing the concentration 10 µg/ ml was prepared in 0.1N HCl , 6.8 P
H
 & phosphate buffer 7.4 P
H
 
respectively, UV spectrum was taken using Double beam UV/VIS spectrophotometer. The solution was scanned in the range of 200 – 
400nm. 
 
Preparation calibration curve: 
10mg of drug was accurately weighed and dissolved in 10ml of 0.1N HCl, 6.8 P
H
, and 7.4 P
H
 in 10 ml volumetric flask, to 
make (1000 µg/ml) standard stock solution (1). Then 1 ml stock solution (1) was taken in another 10 ml volumetric flask to make (100 
µg/ml) standard stock solution (2), then again 1 ml of stock solution (2) was taken in another 10 ml volumetric flask and then final 
concentrations were prepared 2, 4, 5, 10, 15, 20, 25, 30, 35 and 40 µg/ml with 0.1N HCl, 6.8 P
H
, and 7.4 P
H
. The absorbance of standard 
solution was determined using UV/ VIS spectrophotometer at 273nm. Linearity of standard curve was assessed from the square of 
correlation coefficient (r
2
) which determined by least-square linear regression analysis. 
 
Drug – Excipient compatibility studies: 
Fourier Transform Infrared (FTIR) spectroscopy: 
The physical properties of the physical assortment were comparing with those of esomeprazole pure drug. Samples was 
assorted comprehensively through 100mg potassium bromide IR powder as well as compacted under vacuum at a pressure of 
concerning 12 psi for 3 minutes. The ensuing disc was mounted in an appropriate holder in Perkin Elmer IR spectrophotometer and the 
IR spectrum was recorded from 3500 cm to 500 cm. The resultant spectrum was compared for any spectrum changes. 
[3,4]
 
 
Preformulation parameters: 
The quality of tablet, once formulated by rule, is generally dictated by the quality of physicochemical properties of blends. 
There are many formulations and process variables involved in mixing and all these can affect the characteristics of blends produced. 
The various characteristics of blends tested as per Pharmacopoeia. 
[5-7]
 
 
Formulation development of Tablets: 
Preparation of tablets: 
Direct compression method: Different tablets formulations were prepared by direct compression technique. All 
powders were passed through 60 mesh. Required quantities of drug and polymers were mixed thoroughly Magnesium stearate 
was added as lubricant. Talc was used as glidant. Micro crystalline cellulose was used as diluent. Finally the powder mix was 
subjected to compression after mixing uniformly in a polybag. Prior to compression, the blends were evaluated for several 
tests. 
[8,9]
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Table 1: Formulation composition for Esomeprazole tablets. 
 
 
 
 
 
 
 
 
 
 
 
All are expressed in mg. 
 
RESULTS AND DISCUSSION: 
Evaluation of Esomeprazole controlled release tablets: 
Analytical Method: 
Graphs of Esomeprazole were taken in Simulated Gastric fluid (pH 1.2) and in pH 6.8 phosphate buffer at 238 nm and 236 nm 
respectively. 
Table 2:  Observations for graph of Esomeprazole in 0.1N HCl (238nm). 
 
Conc.[µg/l] Absorbance 
0 0 
5 0.110 
10 0.214 
15 0.304 
20 0.407 
25 0.510 
30 0.621 
35 0.718 
40 0.815 
 
 
 
Figure 1: Standard graph of Esomeprazole in 0.1N HCl. 
 
Table 3: Observations for graph of Esomeprazole in pH 6.8 phosphate buffer (236nm). 
 
Conc.[µg/l] Absorbance 
5 0.098 
10 0.195 
15 0.298 
20 0.392 
25 0.490 
30 0.595 
35 0.690 
40 0.776 
 
INGREDIENTS F1 F2 F3 F4 F5 F6 F7 F8 F9 
Esomeprazole 20 20 20 20 20 20 20 20 20 
Eudragit S-100 20 40 - - - - 20 20 - 
Eudragit L-100 - - 20 40 - - 20 - 20 
Eudragit RSPO - - - - 20 40 - - 20 
Talc 3 3 3 3 3 3 3 3 3 
Magnesium stearate 3 3 3 3 3 4 3 3 3 
Di.Calcium Phosphate Qs Qs Qs Qs Qs Qs Qs Qs Qs 
Total Weight 100 100 100 100 100 100 100 100 100 
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Figure 2: Standard graph of Esomeprazole pH 6.8 phosphate buffer (236nm). 
 
Table 4: Preformulation parameters of powder blend: 
 
Formulation Code Angle of Repose Bulk density (gm/ml) Tapped density (gm/ml) Carr’s index (%) Hausner’s Ratio 
F1 24.13 0.51±0.02 0.53±0.03 15.96±0.08 0.98±0.05 
F2 23.36 0.50±0.03 0.54±0.06 16.18±0.04 1.03±0.06 
F3 24.69 0.49±0.09 0.57±0.04 14.68±0.07 1.08±0.09 
F4 25.26 0.52±0.07 0.53±0.06 16.59±0.09 1.01±0.03 
F5 24.98 0.53±0.07 0.58±0.05 15.84±0.06 1.1±0.07 
F6 24.12 0.54±0.02 0.55±0.08 14.98±0.02 1.10±0.08 
F7 23.86 0.55±0.08 0.58±0.03 15.98±0.04 0.94±0.06 
F8 25.02 0.56±0.02 0.63±0.04 14.84±0.03 1.14±0.08 
F9 24.98 0.54±0.03 0.53±0.04 16.98±0.08 1.09±0.03 
 
Tablet powder blend was subjected to various pre-formulation parameters. The angle of repose values indicates that the 
powder blend has good flow properties. The bulk density of all the formulations was found to be in the range of 0.49±0.09 to 
0.56±0.02 (gm/cm3) showing that the powder has good flow properties. The tapped density of all the formulations was found to be in 
the range of 0.53±0.03 to 0.58±0.05 showing the powder has good flow properties. The compressibility index of all the formulations 
was found to be ranging between 14.68±0.07 to 16.98±0.08 which shows that the powder has good flow properties. All the 
formulations has shown the hausner’s ratio ranging between 0.94±0.06 to 1.14±0.08 indicating the powder has good flow properties. 
 
Quality Control Parameters for Esomeprazole tablets: 
Esomeprazole Tablet quality control tests such as weight variation, hardness, and friability, thickness, Drug content and drug 
release studies in different media were performed on the compression tablet. 
[10-12]
 
 
Table 5: In vitro quality control parameters for Esomeprazole tablets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All the parameters such as weight variation, hardness, friability, thickness and drug content were found to be within limits. 
Time (hrs) F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
1 6.98 6.42 7.08 7.35 15.55 6.42 14.21 10.53 10.11 
2 7.86 8.52 18.73 14.39 19.94 12.59 19.65 19.29 16.74 
4 14.65 13.26 27.74 19.22 28.33 24.26 24.98 29.21 28.37 
6 18.64 22.73 39.11 24.21 35.29 38.12 28.76 36.36 33.44 
8 23.36 33.79 47.44 31.42 40.11 49.94 35.34 41.39 43.45 
10 29.82 41.21 58.35 39.73 48.87 57.15 44.50 49.62 49.34 
12 34.61 50.22 63.53 51.29 55.83 69.93 54.56 58.01 58.11 
14 43.07 57.33 69.89 60.11 61.12 75.66 61.05 65.47 66.94 
16 48.71 68.03 74.29 72.14 69.76 81.78 64.98 73.55 69.38 
18 57.22 74.39 79.01 78.77 73.58 85.19 72.03 77.48 74.14 
20 68.35 76.15 81.43 83.64 79.56 91.26 76.92 80.35 79.76 
22 77.23 81.12 83.36 86.89 85.32 94.18 85.88 84.66 84.88 
24 86.77 88.27 90.67 91.03 91.93 97.47 91.12 90.87 89.98 
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In-Vitro Drug Release Studies: 
 
Table 6: Cumulative percent drug release of Esomeprazole Tablets: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Dissolution graphs for the formulations F1-F3. 
 
 
 
Figure 4: Dissolution graphs for the formulations F4-F6. 
 
Formulation 
codes 
Weight 
variation(mg) 
Hardness 
(kg/cm
2
) 
Friability 
(%) 
Thickness 
(mm) 
Drug 
content (%) 
F1 100±0.48 4.5±0.41 0.50±0.13 3.8±0.29 99.17±0.73 
F2 101.4±0.86 4.1±0.23 0.59±0.48 4.1±0.24 98.96±0.36 
F3 99.1±0.86 3.9±0.16 0.61±0.29 3.4±0.14 99.74±0.64 
F4 101.6±0.86 3.5±0.39 0.75±0.66 4.9±0.57 98.96±0.11 
F5 98.9±0.11 4.2±0.22 0.56±0.25 3.9±0.35 99.59±0.35 
F6 99.8±0.32 4.4±0.56 0.65±0.18 4.1±0.23 99.87±0.13 
F7 98.4±0.53 3.8±0.12 0.59±0.74 3.4±0.24 98.85±0.37 
F8 101.3±0.42 3.3±0.11 0.49±0.33 3.3±0.61 99.36±0.31 
F9 99.1±0.44 3.8±0.37 0.57±0.37 3.5±0.27 99.61±0.44 
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Figure 5: Dissolution graphs for the formulations F7-F9. 
 
From the dissolution data it was evident that the formulations prepared with Eudragit-RSPO as polymer were suitable to 
retard the drug release up to desired time period i.e., 24 hours. 
Whereas the formulations prepared with Eudragit RSPO retarded the drug release in the concentration of 20 mg (F-6 
Formulation) showed required release pattern i.e., retarded the drug release upto 24 hours and showed maximum of 97.47% in 24 
hours with good retardation. 
 
Application of Release Rate Kinetics to Dissolution Data: 
Various models were tested for explaining the kinetics of drug release. To analyze the mechanism of the drug release rate 
kinetics of the dosage form, the obtained data were fitted into zero order, first order, Higuchi, Korsmeyer-Peppas and Hixson Crowell 
release model. 
[13-15]
 
 
Table 7: Different kinetic models for tablets: 
 
F.Code Zero order First order Higuchi Peppas Hixson Crowell 
F1 0.9898 0.9810 0.9337 0.9656 0.9856 
F2 0.9939 0.9787 0.9072 0.9660 0.9863 
F3 0.9769 0.9971 0.9728 0.9781 0.9959 
F4 0.9853 0.9580 0.9196 0.9748 0.9711 
F5 0.9604 0.9869 0.9878 0.9864 0.9827 
F6 0.9929 0.9848 0.9461 0.9979 0.9951 
F7 0.9667 0.9653 0.9531 0.9517 0.9706 
F8 0.9727 0.9877 0.9814 0.9928 0.9886 
F9 0.9829 0.9869 0.9728 0.9967 0.9917 
 
Optimized Formulation for Release Kinetics Graphs: 
 
 
 
Figure 6(a): Zero order release. 
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Figure 6(b): First order release. 
 
 
 
Figure 6(c): Higuchi. 
 
 
 
Figure 6(d): Karsmayer peppas. 
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Figure 6(e): Hixson Crowell. 
 
CONCLUSION 
The aim of the present study was to develop a controlled release formulation of proton pump inhibitor (PPI) of 
Esomeprazole. To maintain constant therapeutic levels of the drug for over 24 hrs. Esomeprazole was selected as model drugs. 
Various formulations were developed with different polymers for each drug molecule. To achieve pH-independent drug release of 
formulations, pH modifying agents (buffering agents) were used. The precompression blend of all formulations was subjected to 
various flow property tests and all the formulations were passed the tests. 
 
Esomeprazole: 
Esomeprazole dose was fixed as 20 mg. Total weight of the tablet was considered as 100 mg. Polymers were used in the 
concentration of 20 and 40 mg concentration. All the formulations were passed various physicochemical evaluation parameters and 
they were found to be within limits. Whereas from the dissolution studies it was evident that the formulation (F-6) showed better and 
desired drug release pattern i.e., 97.47 % in  24 hours. It followed zero order release kinetics mechanism. The best formulation was 
repeated again for reproducibility, and all the quality control tests were done for conformation. The results were found to be super 
imposable with each other. The optimized formula shall be utilized for the formulation development and other studies like bio-
equivalence study, for successful launching of the product. 
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